Oral Abstracts2 9 0 THURSDAY Supplement to Transplantation July 27, 2008, Volume 86 Number 2S was Lebanese. Indications for liver transplantation were as follows: hepatitis C cirrhosis (n=29); hepatitis B cirrhosis (n=13); cryptogenic cirrhosis (n=6); hepatitis B and C co-infection cirrhosis (n=1), primary biliary cirrhosis (n=1) and hepatocellular carcinoma (n=24). All patients were either on the KFSH waiting list for liver transplantation or were denied liver transplantation in KFSH or Egypt due to unsuitable medical condition such as old age or advanced hepatocellular carcinoma (HCC). One year, 3-year and 5-year cumulative patient survival rates were 83%, 62%, and 62% respectively compared to 92%, 84% and 71% in KFSH. Median survival time of the patients was signifi cantly less than that of those transplanted in KFSH (p=0.01). One year, 3-year and 5-year cumulative graft survival rates were 81%, 59%, and 59% respectively compared to 90%, 84% and 71% in KFSH. Of the surviving patients, many suffered from multiple other morbidities. Compared to the patients transplanted in KFSH, the incidence of complications was signifi cantly higher especially biliary complications (p=0.01), sepsis (p=0.003), rejection (p=0.04), metastasis (p=0.03) and acquired HBV infection posttransplant (p=0.02). In addition, requirement of postoperative interventions (radiologic and laparotomy) as well as hospital admissions, were signifi cantly higher hence constituting a higher burden on the resources of the hospital. Conclusion: Our data shows clearly that there is a high mortality and morbidity rate in Saudi and Egyptian patients receiving transplantation in China. This could be related to poor selection criteria, long warm ischemia time, or poor post transplant care. . Although cadaveric liver transplantation in China could be an option for desperate Egyptian and Saudi patients with end stage liver disease, patients and clinicians should be aware of the possible outcomes LATE BREAKING

Conclusion:While policies focused on uDCD may increase overall DD rates, increases in DD from policies that focus on cDCD come at the expense of DBD. We conclude that cDCD negatively impacts the number of donations from brain dead donors and may lead to an overall reduction in the number of transplants performed due to reduced organ retrieval rates. 2546A Phase 1b, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Single-Dose, Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of ASKP1240 in de novo Kidney Transplantation

Figure 2. Tacrolimus blood levels ( g/l) against time postdose (hours). R1, R2, R3; rectal administration, PO1, PO2, PO3; oral administration. Discussion: To our surprise tacrolimus was hardly absorbed after sublingual administration. A possible explanation for the results contradictory with the study of Reams et al. could be that in the study of Reams et al. patients were not told not to swallow and to spit out saliva and rinse the mouth. Therefore oral intake of tacrolimus can not be excluded. After rectal administration of suppositories in a dose of 0,23-0,27 mg/kg tacrolimus, blood levels seemed to be comparable with blood levels after oral administration of 0,1 mg/kg. Peak blood levels occurred later and the absorption period seems to be prolonged after rectal in comparison with oral administration. Conclusion: In this pilot study tacrolimus was hardly absorbed after sublingual administration. After rectal administration in suppositories tacrolimus is well absorbed. These results indicate that sublingual administration of tacrolimus is no but rectal administration probably is a useful alternative for oral administration. Further investigation is warranted in order to establish correct dose and pharmacokinetic parameters for rectal administration. Background: CP-690,550 (CP) is an orally active inhibitor of Janus kinase, currently in Phase 2 trials for kidney transplantation and autoimmune diseases. Objective: To characterize the CP-690,550 pharmacokinetic (PK) profi le in de novo kidney transplant patients enrolled in a 6-month, Phase 2, randomized, open-label, multicenter, active comparator-controlled, parallel group study. Methods: Plasma samples were collected in patients receiving 15 mg (N=19) and 30 mg (N=20) of CP-690,550 twice daily (BID) using a combination of sparse (predose samples on Days 1, 3, and 14 and Months 1, 3, and 6 posttransplant) and dense (samples at 0.5, 1, 2, 4, 8, and 12 hours post-dose on Days 1 and 3 in approximately 40% of the patients) sampling strategies. PK data were analyzed using noncompartmental techniques, where possible, and population modeling techniques. Results: The absorption of CP-690,550 on Day 1 post-transplant was decreased with variable time to peak concentration (T max ) between 1 and 12 hours postdose. The PK profi les on Day 3 showed rapid and consistent absorption, and rapid elimination (Table 1), consistent with historical healthy-volunteer data. While increases in median area under the curve (AUC 0-t ) estimates were roughly dose proportional, C max increases tended to be less than proportional between 15 mg and 30 mg BID. Over the 6-month period, geometric mean trough concentrations of CP-690,550 were 17 ng/mL and 32 ng/mL for the 15 mg and 30 mg BID doses, respectively, and were highly variable (coeffi cients of variation [CV] of ~100%). Concentrations at 4 hours post-dose showed higher correlation with AUC 0-t (r=0.92) than the trough concentration (r=0.63).

Inflow of blood into intraarterial catheters in dogs following single and continuous injections of saline, contrast medium and polysaccharide fluids were analysed with special reference to the influence of their density and viscosity. Clot formation was also analysed and the favourable properties of one variant of the polysaccharide fluids were demonstrated.

No abstract